Published by Josh White on 20th January 2021
(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Wednesday that the recruitment of 120 Covid-19 patients into its phase 2 trial evaluating an inhaled formulation of interferon-beta-1a, 'SNG001', conducted in the home setting, had now been completed.